Justin Schweitzer
Optometrist · Sioux Falls, SDNPI 1023047867
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.6%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by AbbVie at 25.2% of the total. 2025 is the largest year on record at $154,083, 2.7 times the $57,088 reported in 2019. Among optometrist clinicians in SD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,166 payments — averaging $646.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$190K
- Bausch & Lomb Americas Inc.$138K
- Reichert, Inc.$73K
- Dompe US, Inc.$52K
- Aerie Pharmaceuticals, Inc.$51K
- Tarsus Pharmaceuticals, Inc.$50K
- plus $199K from 27 others
Across 6 payments — averaging $18,447 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alcon Research LLC$103K
- Novartis$7K
- AbbVie$109
What the payments were for
- Consulting fees$238,74032%
- Speaking & faculty fees$426,29157%
- Travel & lodging$49,8967%
- Food & beverage$25,4873%
- Education$1180%
- Gifts$12,9502%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DURYSTA$84,559
- MIEBO$79,309
- XIIDRA$60,146
- VYZULTA$59,879
- Rhopressa$58,585
- Rocklatan$54,317
- VUITY$54,288
- Oxervate$50,697
- XDEMVY$42,760
- LUMIGAN$31,819
- CEQUA$29,717
- RETEVAL$17,250
- EyeKinetix$12,950
- LOTEMAX SM$12,388
- COMBIGAN$11,157
- VEVYE$10,968
- OMNI(R) SURGICAL SYSTEM (US)$8,593
- iStent Trabecular Micro-Bypass Stent System$8,552
- iStent inject Trabecular Micro-Bypass Stent System$8,209
- OMNI$7,375
How this compares
$753,482 in reported general payments places this provider in the 95th percentile of 206 optometrist providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 11 | $527,924 |
| XdemvyLotilaner | 41 | $75,410 |
| VyzultaLatanoprostene Bunod | 129 | $53,314 |
| RestasisCyclosporine | 50 | $46,768 |
| LumiganBimatoprost | 108 | $43,306 |
| CombiganBrimonidine Tartrate/Timolol | 125 | $31,026 |
| RocklatanNetarsudil Mesylat/Latanoprost | 85 | $29,145 |
| RhopressaNetarsudil Mesylate | 37 | $12,004 |
| Lotemax SmLoteprednol Etabonate | 48 | $11,969 |
| XiidraLifitegrast | 15 | $11,720 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 76 | $11,653 |
| Prednisolone Acetate | 280 | $9,720 |
| Alphagan PBrimonidine Tartrate | 42 | $9,138 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 40 | $8,157 |
| Cyclosporine | 11 | $5,108 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $51,741 | $527,92411 claims |
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $190,028 | $130,239325 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $50,378 | $75,41041 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra | $138,402 | $65,033144 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $50,959 | $41,148122 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Loteprednol Etabonate | $9,806 | $13,36162 claims |
| AlconSimbrinza | $25,742 | $8,15740 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 206 optometrist providers in South Dakota.
Other optometrist in Sioux Falls
- Mitchel IbachSioux Falls$395K
- Jason SchmitSioux Falls$79K
- Jeffery SaylerSioux Falls$8K
- Kayla KarpukSioux Falls$6K
- Travis LehrSioux Falls$5K
- Matthew ClarkeSioux Falls$5K
- Ryan HaiarSioux Falls$4K
- Kristen KramlichSioux Falls$4K
- Joshua TimsSioux Falls$4K
- Larae ZimprichSioux Falls$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.